Progressive fibrosing interstitial lung disease: high care needs, high costs

    This is a preview of subscription content, log in to check access.

    Notes

    1. 1.

      The study was funded by Boehringer Ingelheim Pharma GmbH.

    Reference

    1. Olson AL, et al. Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA. Advances in Therapy : 12 May 2020. Available from: URL: http://doi.org/10.1007/s12325-020-01380-4

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    Progressive fibrosing interstitial lung disease: high care needs, high costs. PharmacoEcon Outcomes News 855, 25 (2020). https://doi.org/10.1007/s40274-020-6890-6

    Download citation